Argus Research Upgrades Regeneron Pharmaceuticals to Buy, Announces $850 Price Target

Benzinga · 1d ago
Argus Research analyst Jasper Hellweg upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Hold to Buy and announces $850 price target.